Background: Understanding natural HIV control may lead to new preventative or ther-
| INTRODUCTION
The natural course of human immunodeficiency virus (HIV) infection progresses through three typical phases. 1, 2 During the acute phase, viral load (plasma HIV RNA concentration) peaks, up to >10 6 copies/ mL, and CD4+ cell count declines. In a few weeks, CD4 count partially recovers and viral load decreases to a steady state known as the set point. This is the chronic phase that can last for months or years. Without antiretroviral therapy (ART), eventually viral loads increases and CD4 levels decline, leading to acquired immunodeficiency syndrome (AIDS). However, a small subset of HIV-infected individuals, the HIV controllers, maintain normal CD4 counts (>threshold of 500 cells/μL blood) and control viral loads to low (<2000 copies/mL) or undetectable level (<50 copies/mL) by conventional assays, in the absence of ART. 2 This natural form of HIV control is widely considered an ideal model to inform the development of new vaccines or therapeutics. 2 While there are several proposed mechanisms accounting for the level of viral containment in HIV controllers, recent studies suggested that host genetics and immunological responses play an important role. 3 Several genotypes of the major histocompatibility complex (MHC), or human leukocyte antigen (HLA) in humans, including HLA-B*57 and HLA-B*27, appear to be the dominant genetic correlate of protection. [4] [5] [6] [7] Accumulating evidence suggested that protective HLA molecules may contribute to viral control by enhancing CD8+ T-cell antiviral efficacy in HIV controllers. 4 and Mamu-B*17 33 MHC class I alleles. Mamu-B*08 and the human HLA-B*27 were found to bind peptides with sequence similarity. 34 The availability of rhesus macaques has been greatly reduced due to a ban of their export from India (the major source) and most other south Asian countries. 35 Cynomolgus macaques (Macaca fascicularis) have now become by far the most internationally traded NHP for laboratory experiments. 22 The largest laboratory supply of cynomolgus macaques is available from the island of Mauritius. The Mauritian cynomolgus macaques (MCMs) descended from a small group of founder animals and are characterized by limited MHC diversity, with only seven haplotypes, named M1 through M7. 36, 37 This helps reduce variability between animals and thus reduce animal numbers needed to achieve statistically significant results, making them a practically useful animal model in HIV studies. 27 Simian immunodeficiency virus control phenotypes have also been observed in MCMs; however, the underlying factors are poorly understood. A major study in this field suggested that the M1 or M7 MHC haplotypes may be correlates of protection. 38 Here, we report that the combination of M3 and M4 MHC haplotypes may be a SIV control genotype in MCMs.
| MATERIALS AND METHODS

| Humane care guidelines
Fourteen female Mauritian cynomolgus macaques (Macaca facicularis)
from Bioculture (Mauritius) Ltd were used in a pre-study to optimize immunization condition, MHC haplotype selection, and titration of SIVmac251 for repeated low-dose intravaginal challenge for a large vaccine efficacy study. The vaccine candidate was SIV peptides derived from the sequences of the protease cleavage sites, delivered by recombinant vesicular stomatitis virus and nanoparticles (the PCS vaccine). Eight monkeys received immunization and six monkeys were controls (Table S1 ). The animal work was performed in accordance Animals were observed twice daily by the PI, a co-investigator, or the veterinary staff for signs of clinical illness.
| SIV challenge
The 14 animals were intravaginally challenged with 1000 TCID 50
SIVmac251 (Desrosiers 2010-Day 8 viral stock, provided by Drs. Jon
Warren and Nancy Miller, Vaccine Research Program, NIH). The challenge stock titer was based on a previous publication. 39 The challenge was repeatedly carried out until positive plasma viral load (VL) was detected. Two animals that did not show any detectable viral load after four challenges were excluded from study.
| Viral load assay
Nucleic acids were extracted from 1.0 mL plasma using the EasyMag system and reagents (bioMerieux Canada, St Laurent, QC) and eluted into 110 μL buffer. Viral quantitation was performed by qPCR using the ABI 7900HT (Applied Biosystems, Streetsville, Ontario, Canada) and the QuantiTect Probe RT-PCR kit (Qiagen, Toronto, Ontario, Canada) and primers and probe previously described by Horton et al. 40 All plasma viral loads were converted to log10 values prior to further analysis. The viral load assay was validated by direct comparisons with an established assay in the laboratory of Jonathan Heeney (Biomedical Primate Research Center, the Netherlands).
| CD4+ T-cell quantification
An aliquot of non-human primate (NHP) whole blood (100 μL) collected in a heparinized vacutainer tube was transferred into a BD roundbottom FACS tube. The whole blood was stained using 10 μL of NHP T lymphocyte cocktail (BD Biosciences, San Jose, CA, USA) in the dark. 
| MHC genotyping
The cynomolgus macaque MHC haplotype typing was conducted by
Wisconsin National Primate Research Centre Genetics Services.
41,42
3 | RESULTS
| Viral load profiles of SIV-infected macaques with different MHC haplotypes
We conducted a pre-study with Mauritian cynomolgus macaques Table S1) were involved, among which eight were immunized with the PCS vaccine (Table S1 ).
Using this monkey cohort, we took the opportunity to investi- 
| The M3M4 genotype demonstrates enhanced control of SIV infection
We compared the SIV infection profiles of the two M3M4 monkeys versus all the ten non-M3M4 monkeys (Figure 2 ). The M3M4 group showed trends of lower peak and set point viral loads than the non-M3M4 group, as well as higher CD4 counts, which were above the healthy threshold of 500 cells/μL blood, as opposed to the CD4 counts lower than the threshold in non-M3M4 group (Figure 2 ). Our observation is consistent with a previous study on SIV infection in MCMs. The only M3M4 monkey in that study population was found to control SIV, with a viral load profile similar to the two SIV-infected M3M4 monkeys in our study. 45 Altogether, these findings strongly suggest that the M3M4 MHC genotype may play a protective role in controlling SIV infection in MCMs and is worthy of further exploration.
| M3 or M4 haplotype alone is not sufficient to confer SIV control
Among the SIV-infected monkeys, the M3M4 monkeys showed SIV control, but such phenotype was not seen in monkeys with either M3 or M4 haplotype alone (Figure 3 
